Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.48 |
| ▸ | CCR8 | P51685 | 2/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30436741 | 1.00 | KDM4E (0.48) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL21056001 | 0.79 | KDM4E (0.48) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL31049765 | 0.75 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30492588 | 0.74 | CCR1 (0.70) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL564428 | 0.74 | CCR1 (0.70) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL8993652 | 0.72 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL18229257 | 0.72 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL12886445 | 0.71 | MAPT (0.50) | KDM4ELMNAPOLBSMN1; SMN2NPC1 | |
| SCHEMBL13792039 | 0.71 | CCR1 (0.64) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL23784642 | 0.70 | METAP1 (0.47) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630030-B | Novel benzamide derivatives as PPAR-gamma modulators | 梅迪比奥法尔玛公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11267808-B2 | Benzamide derivatives as PPAR-gamma modulators | MEDIBIOFARMA, S.L. (ES) | 2022-03-08 | — | — | US | disclosed |
| EP-3724165-B1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA S L (ES) | 2022-01-12 | — | — | EP | disclosed |
| EP-3724165-B1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA S L (ES) | 2022-01-12 | — | — | EP | disclosed |
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3724165-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2020-10-21 | — | — | EP | disclosed |
| CN-111630030-A | Novel benzamide derivatives as PPAR-gamma modulators | 梅迪比奥法尔玛公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2019115498-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115498-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-20 | — | — | WO | disclosed |
| EP-3498694-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-19 | — | — | EP | disclosed |
| EP-3498694-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | PPARD, PPARG, PPARA | KDM4E 2499/4885LMNA 1898/4885CCR1 2609/4885 |
| US-11267808-B2 | Benzamide derivatives as PPAR-gamma modulators | PPARG, PPARD, PPARA | KDM4E 2485/4885LMNA 1856/4885CCR1 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.